In Morvan’s syndrome without detected antibodies, it is efficient to apply IVIG with subsequent oral therapy by corticosteroids and potassium channel blockers to reduce autonomic symptoms and neuropathic pain. This evidence concerns the gene KCNA3 and Morvan syndrome.